Related by context. All words. (Click for frequent words.) 72 Phase IIIb clinical 69 phase IIb trial 68 phase IIb clinical 68 Phase Ib clinical 67 low dose cytarabine 67 Xelox 67 elotuzumab 67 Tarceva TM 67 randomized multicenter trial 67 Phase Ib II 67 Phase #b/#a 67 randomized Phase 2b 67 HCV RESPOND 2 67 CHAMPION PCI 66 Dacogen injection 66 placebo controlled Phase III 66 dose cohort 66 IMPACT DCM 66 NSABP B 66 MAGE A3 ASCI 66 phase IIa 66 CLARITY study 66 pharmacodynamics PD 66 bortezomib Velcade 66 Phase 1b trial 66 NATRECOR R 66 budesonide foam 66 relapsed MM 66 pomalidomide 66 YONDELIS 66 phase IIa clinical 66 dose escalation clinical 66 phase IIb III 66 Prostate AdenoCarcinoma Treatment 66 Phase IIb III 66 STRIDE PD 66 Pemetrexed 66 Velcade bortezomib 65 oral deforolimus 65 OvaRex ® MAb 65 placebo controlled clinical 65 axitinib 65 multicenter Phase II 65 Phase III randomized controlled 65 fluvastatin 65 Temsirolimus 65 phase IIb 65 mg/m2 cohort 65 neratinib 65 Degarelix 65 randomized blinded 65 5-fluorouracil/leucovorin 65 XL# SAR# 65 Clolar ® 65 mapatumumab 65 HCV SPRINT 65 galiximab 65 phase Ib 65 teriflunomide 65 MERLIN TIMI 65 double blinded randomized 65 iniparib 65 riociguat 65 ZOLINZA 65 pegylated liposomal doxorubicin 65 ENESTnd 65 multicenter randomized controlled 65 Amrubicin 64 forodesine 64 androgen suppression 64 BR.# 64 ENDEAVOR III 64 oxaliplatin Eloxatin 64 liposomal amphotericin B 64 ritonavir boosted 64 Phase IIB 64 sunitinib malate 64 Cloretazine 64 randomized Phase IIb 64 Intervention Effectiveness 64 assessing T DM1 64 BRIM3 64 goserelin 64 phase IIIb 64 cediranib 64 GAMMAGARD 64 multicenter clinical 64 PROSTVAC ® 64 ER CHOP 64 TLK# 64 NATRECOR ® 64 sorafenib Nexavar 64 TELCYTA 64 Androxal TM 64 comparator arm 64 randomized Phase III 64 FOLFOX4 64 Azedra 64 Epirubicin 64 pertuzumab 64 dose escalation phase 64 Pegylated Interferon 64 interferon gamma 1b 64 Bezielle 64 thalidomide Thalomid 64 placebo controlled Phase 64 RE LY 64 CANCIDAS 64 tigecycline 64 INCB# [001] 64 investigational protease inhibitor 64 intermittent dosing 64 Folfox 64 oral ridaforolimus 64 angiographic outcomes 63 doxorubicin docetaxel 63 unfractionated heparin UFH 63 DEB# 63 treatment naive genotype 63 ELACYT 63 divalproex sodium 63 PSMA ADC 63 confirmatory clinical 63 sipuleucel T 63 oblimersen 63 nab paclitaxel 63 Phase IIIb study 63 docetaxel Taxotere ® 63 IL# PE#QQR 63 PEG SN# 63 SPRYCEL ® 63 AVADO 63 temsirolimus 63 Natalizumab 63 Phase 2a trial 63 paclitaxel Taxol R 63 erlotinib Tarceva ® 63 randomized controlled Phase 63 multicenter Phase 63 evaluating tivozanib 63 Doxil ® 63 APTIVUS 63 YERVOY 63 Phase IIIb 63 GOUT 63 glatiramer acetate 63 tolevamer 63 viral kinetics 63 Helicobacter pylori eradication 63 PROSTVAC VF 63 docetaxel chemotherapy 63 CALGB # [002] 63 Asentar 63 efalizumab 63 TOLAMBA 63 ATACAND 63 ORAL HYCAMTIN 63 pharmacokinetic PK study 63 Taxotere ® 63 tanespimycin 63 PRECISE trial 63 tesmilifene 63 Dasatinib 63 Platinol ® 63 eculizumab therapy 63 MGd 63 trastuzumab DM1 T DM1 63 cilengitide 63 refractory chronic lymphocytic 63 metastatic castration resistant 63 APTIVUS r 63 oral Hycamtin 63 ANCHOR trial 63 KRAS status 63 Targretin 63 Cimzia TM 63 visilizumab 63 recurrent GBM 63 CIMZIA ™ 63 Phase Ib study 63 multicentre randomized 63 neurologic progression 63 Nebulized 63 pharmacodynamic effects 63 NO# [002] 63 pivotal bioequivalence 63 Phase 1b clinical 63 estramustine 62 dacarbazine chemotherapy 62 IMPACT IMmunotherapy 62 multicenter phase 62 Irinotecan 62 azacitidine 62 bendamustine 62 vandetanib 62 recurrent malignant glioma 62 Sipuleucel T 62 Hormone Refractory Prostate Cancer 62 canakinumab 62 bicifadine 62 Torisel 62 trastuzumab emtansine T DM1 62 Fondaparinux 62 TAXUS VI 62 vicriviroc 62 nucleotide analog 62 phase IIb study 62 USL# 62 Ranolazine 62 ENDEAVOR IV 62 decitabine 62 melphalan prednisone 62 Onrigin TM 62 Cloretazine ® 62 placebo controlled trials 62 oral rivaroxaban 62 AIR CF2 62 IFN alfa 62 Traficet EN 62 PRE SURGE 62 crizotinib PF # 62 HGS# 62 LUX Lung 62 Dacogen decitabine 62 nitazoxanide 62 lintuzumab 62 CARE HF 62 RECORD1 62 REMINYL ® 62 pegylated interferon alpha 62 Neulasta ® 62 insulin detemir 62 Hydroxyurea 62 phase III isavuconazole 62 ORENCIA R 62 metastatic malignant 62 Azacitidine 62 PERSEUS 62 standard chemotherapy regimen 62 Phase IIb clinical trials 62 Acute Decompensated Heart Failure 62 MIST II 62 EmbraceAC 62 nalbuphine ER 62 PegIFN RBV 62 viral kinetic 62 Alocrest 62 prucalopride 62 AEGR 62 multicenter multinational 62 Randomized Phase 62 Randomized controlled 62 abacavir lamivudine 62 EndoTAG TM -1 62 Taxotere chemotherapy 62 Aortic Stenosis 62 mRCC 62 pegylated interferon alfa 2b 62 Advagraf 62 Phase #b/#a clinical 62 Phase III VISTA 62 thorough QT 62 phase Ib clinical 62 recurrent glioblastoma multiforme 62 vidofludimus 62 rFVIIa 62 zalutumumab 62 Virologic 62 Thalomid ® 62 PEGylated interferon beta 1a 62 ADAGIO study 62 EOquin TM 62 Nilotinib 62 desvenlafaxine succinate 62 imatinib therapy 62 SUTENT ® 62 HuMax EGFr 62 ARCOXIA 62 Decitabine 62 Phase 2b trial 62 lomitapide 62 Phase IIb clinical 62 XELOX 62 CAMMS# 62 mertansine 62 ToGA 62 ORENCIA ® 62 ascending dose 62 dacetuzumab 62 Phase 2b study 62 Phase 2a clinical 62 Pivotal Phase 62 Telcyta 62 rFSH 62 ADVANCE PD 62 5 Fluorouracil 62 hA# 62 mycophenolate mofetil 62 DAPT 62 posaconazole 62 multicenter randomized placebo controlled 62 peginterferon alpha 2a 61 Dose escalation 61 enzastaurin 61 double blinded placebo 61 gefitinib Iressa 61 clinical pharmacology studies 61 pharmacokinetic PK 61 ribavirin RBV 61 gadobutrol 61 zoledronate 61 doxorubicin cyclophosphamide 61 LEP ETU 61 SABCS 61 pharmacokinetics PK 61 APPRAISE 61 satraplatin Phase 61 relapsing remitting MS RRMS 61 Plicera 61 lapatinib Tykerb 61 lumiliximab 61 Omnitarg 61 esophageal candidiasis 61 CLORETAZINE TM VNP#M 61 Cloretazine R VNP#M 61 iniparib BSI 61 invasive aspergillosis 61 Tanespimycin 61 virological response 61 PEG IFN 61 mycophenolate mofetil MMF 61 salmeterol fluticasone 61 FOLFIRI 61 TYGACIL 61 custirsen 61 randomized controlled clinical 61 plus prednisone 61 substudy 61 Phase IIa clinical 61 Revlimid lenalidomide 61 Clinical Antipsychotic Trials 61 NSABP C 61 ritonavir boosted atazanavir 61 TMC# C# 61 levosimendan 61 Phase 1a clinical 61 MADIT II 61 cisplatin vinorelbine 61 Fludara 61 THALOMID 61 azilsartan medoxomil 61 corticosteroid dexamethasone 61 alvespimycin 61 NovoTTF 61 Tumor Response 61 Pegylated interferon 61 VNP#M 61 adalimumab Humira 61 interferon ribavirin 61 refractory CLL 61 EURIDIS 61 ixabepilone 61 active comparator 61 Onrigin 61 cyclophosphamide doxorubicin vincristine 61 AEG# 61 urocortin 2 61 Tipranavir 61 Femara letrozole 61 HSCT 61 platelet inhibitor 61 relapsing multiple sclerosis 61 ongoing Phase 1b 61 bevacizumab Avastin 61 prospective observational 61 GW# [003] 61 Motavizumab 61 lenalidomide dexamethasone 61 elacytarabine 61 bolus dose 61 Trandolapril 61 DES implantation 61 herpetic keratitis 61 CALGB 61 pharmacokinetic studies 61 hoFH 61 balsalazide tablet 61 IIb clinical trial 61 nesiritide 61 sitaxsentan 61 CLIRS trial 61 ABCSG 61 Erlotinib 61 paliperidone ER 61 demonstrated antitumor activity 61 QLT# 61 alfa 2a 61 dose cohorts 61 RE LY ® 61 TELINTRA 61 PEGINTRON TM 61 INTERCEPT platelets 61 Phase IIa trial 61 Phase III ThermoDox 61 epoetin alpha 61 Peginterferon 61 QD dosing 61 CR nPR 61 Vidaza azacitidine 61 nonclinical studies 61 Keppra XR 61 oral methylnaltrexone 61 CHOP chemotherapy 61 eltrombopag 61 ACUITY trial 61 interferon alfa 61 midstage trials 61 rilonacept 61 Pazopanib 61 telaprevir dosing 61 paclitaxel poliglumex 61 Randomised Study 61 Genz # 61 trastuzumab Herceptin R 61 pharmacokinetic characteristics 61 NEVO ™ 61 CIMZIA TM certolizumab pegol 61 relapsed refractory multiple myeloma 61 Telintra 61 Phase Ib 61 Zolinza 61 Moxifloxacin 61 TMC# r 61 Pivotal Phase III 61 gemcitabine Gemzar 61 KRAS mutations occur 61 mCRC patients 61 concurrent chemoradiation 61 Randomized Evaluation 61 FOLFIRI alone 61 induce remission 61 Phase #/#a trial 61 Pegylated Liposomal Doxorubicin 61 BCIRG 61 Raptiva ® 61 huN# DM1 61 ZACTIMA 60 midstage clinical 60 Elitek 60 INTEGRILIN ® 60 plus dexamethasone 60 prospectively defined 60 Triapine R 60 sunitinib 60 fosbretabulin 60 Ixempra 60 Fabry Disease 60 Phase III Clinical Trials 60 R# #mg BID 60 OPT CHF 60 HuMax CD4 60 protease inhibitor PI 60 Phase 2b clinical 60 candidemia 60 FOLFOX 60 BRIM2 60 ChronVac C R 60 PERSEUS clinical program 60 zoledronic acid Zometa 60 CRMD# 60 symptomatic VTE 60 Jevtana 60 Pivotal Study 60 rALLy clinical trial 60 postoperative chemotherapy 60 CIMZIA TM 60 PROSTVAC TM 60 TEMSO 60 abiraterone acetate 60 Saxagliptin 60 Ophena TM 60 Neupogen ® 60 alpha 2a 60 potentially hepatotoxic 60 ritonavir boosted lopinavir 60 trabectedin 60 Arranon 60 placebo controlled studies 60 invasive candidiasis 60 FOLPI 60 Taxotere docetaxel 60 LY# [003] 60 Phase 2b kidney transplant 60 latrepirdine 60 AIR CF1 60 CoFactor 60 TORISEL 60 lanthanum carbonate 60 postmenopausal osteoporotic women 60 dose dexamethasone 60 subanalysis 60 PROMACTA 60 Fingolimod 60 Solorel 60 investigational monoclonal antibody 60 TASKi3 60 generation purine nucleoside 60 octreotide acetate 60 alkylating agent 60 TO AVOID PREGNANCY WHILE 60 liposomal doxorubicin 60 chemoradiotherapy 60 tramiprosate Alzhemed TM 60 Faslodex 60 vinorelbine 60 EXPAREL ™ 60 docetaxel Taxotere R 60 APEX AMI 60 ara C 60 OVATURE 60 hepatorenal syndrome 60 dacarbazine 60 ganaxolone 60 peg interferon 60 torcetrapib atorvastatin 60 carboplatin paclitaxel 60 Safinamide 60 metastatic CRC 60 Flu Cy 60 EFAPROXYN 60 Valsartan 60 Octreolin 60 steroid dexamethasone 60 Quinamed 60 aflibercept 60 Heterozygous Familial Hypercholesterolemia 60 Phase 1b 60 Genentech Rituxan 60 deferiprone 60 paclitaxel Taxol ® 60 OHR/AVR# 60 HGS ETR2 60 candesartan cilexetil 60 IGF 1R inhibitor 60 sulodexide 60 Dapagliflozin 60 novel VDA molecule 60 Fludarabine 60 Targretin capsules 60 leukemia AML 60 IMA# 60 dalteparin 60 oral diclofenac 60 pharmacodynamic PD 60 Vitaxin 60 lenalidomide Revlimid R 60 NEUVENGE 60 acute mania 60 CUSTOM III 60 cisplatin gemcitabine 60 anti CD3 antibody 60 rituximab Rituxan 60 TBC# 60 nonrandomized 60 ziprasidone 60 oxymorphone ER 60 RELOVAIR ™ 60 zafirlukast 60 Proellex TM 60 Enzastaurin 60 VFEND 60 MOZOBIL 60 dosing cohorts 60 resected pancreatic cancer 60 cancer mCRC 60 HoFH 60 antiviral efficacy 60 EVEREST II 60 LCP Tacro 60 brivaracetam 60 ancrod 60 Allovectin 7 ® 60 rindopepimut 60 Aloxi injection 60 pharmacokinetic interactions 60 DCVax R Brain 60 Carotid Revascularization Endarterectomy vs. 60 Nuvion 60 randomized controlled multicenter 60 Omacetaxine 60 intra abdominal abscess 60 Phase III Pivotal 60 Certolizumab pegol 60 dose cyclophosphamide 60 PRIMO CABG 60 ARIXTRA 60 EMPHASIS HF trial 60 celgosivir 60 Phase 1a 60 randomized crossover 60 milatuzumab 60 cetuximab Erbitux 60 evaluating mipomersen 60 LAF# 60 reboxetine 60 eplerenone 60 clinical trial 60 pharmacokinetic PK profile 60 dosing cohort 60 EGFRIs 60 Ziprasidone 60 Myelodysplastic Syndrome MDS 60 TAXOTERE R 60 relapsed ovarian cancer 60 GnRH agonist 60 boosted protease inhibitor 60 UPLYSO 60 R#/MEM # 60 trastuzumab Herceptin 60 peginterferon alfa 60 insulin glulisine 60 LNG IUS 60 Arzerra ofatumumab 60 darunavir ritonavir 60 lenalidomide Revlimid 60 Zometa zoledronic acid 60 GLP1 agonist 60 telaprevir dosed 60 SUCCEED trial 60 Noxafil 60 LUMINATE 60 allogeneic HSCT 60 DASISION 60 prospective multicentre 60 nucleotide analogue 60 Xeloda ® 60 MIVI III 60 blinded randomized placebo controlled 60 Betaferon ® 60 Kepivance 60 unresectable HCC 60 intravenous immunoglobulin 60 cetuximab Erbitux ® 60 cannabinor 60 Sprycel dasatinib 60 Refractory Angina 60 CYPHER Stent 60 recurrent metastatic 60 IMPROVE IT 60 placebo controlled randomized 60 FavId 60 Navelbine ® 60 HeFH 60 motesanib diphosphate 60 Nexavar sorafenib 60 clazosentan 60 infusional 60 intravenous dosing 60 BAY #-# 60 REVLIMID lenalidomide 60 pamidronate 60 locoregional 60 AIM HIGH 59 Vectibix panitumumab 59 vorinostat 59 Aflibercept 59 ELOXATIN 59 Panzem R NCD 59 RSD# oral 59 Zytiga 59 TORISEL TM 59 adriamycin 59 Telithromycin 59 genotypic resistance 59 APEX AMI trial 59 hematologic parameters 59 intravenous cyclophosphamide 59 MYCAMINE 59 vildagliptin 59 K ras mutations 59 Losartan 59 adjuvant colon cancer 59 etanercept Enbrel 59 paroxetine Paxil 59 docetaxel Taxotere 59 liver transplant recipients 59 BEACOPP 59 REVLIMID ® 59 Parathyroid Hormone 59 Phase III clinical 59 Non inferiority 59 Val HeFT 59 Zenvia Phase III 59 multicenter prospective 59 olmesartan 59 velafermin 59 Zarnestra 59 PEGylated interferon 59 MYDICAR 59 Phase Ia 59 chronic lymphocytic leukemia CLL 59 superficial bladder cancer 59 TAXUS TM 59 inhibitor RG# 59 maximally tolerated dose 59 bortezomib Velcade R 59 biliary tract cancer 59 hypomethylating agents 59 prasugrel Effient 59 Double Blind Randomized 59 PEG INTRON R 59 Acute Ischemic Stroke 59 multicenter randomized Phase 59 Cariprazine 59 darunavir r 59 CIP TRAMADOL ER 59 GAMMAGARD LIQUID 59 APF# Phase 59 observational cohort study 59 eptifibatide 59 Platinol 59 VELCADE melphalan 59 micafungin 59 mg/m2 dose 59 Initiate Phase 59 cetuximab Erbitux R 59 HCD# [002] 59 ExTRACT TIMI 59 inhaled iloprost 59 glatiramer 59 Zenvia ™ 59 glufosfamide 59 pharmacodynamic profile 59 ARB telmisartan 59 DCVax ® Brain 59 rufinamide 59 R lenalidomide 59 non nucleoside inhibitor 59 Eltrombopag 59 pegylated interferon alfa 59 Taxol paclitaxel 59 intravitreal insert 59 Vorapaxar 59 certolizumab 59 Betaferon R 59 AZILECT R 59 GRNVAC1 59 adenoma recurrence 59 Phase #/#a 59 MEND CABG 59 gemcitabine carboplatin 59 Fulvestrant 59 tolvaptan 59 Nesiritide 59 Zavesca R 59 Hycamtin 59 ILLUMINATE 59 Pirfenidone 59 icatibant 59 MyVax R 59 TAXOTERE ® 59 Hodgkin lymphoma HL 59 Phase Ib IIa 59 FOLFOX chemotherapy 59 delafloxacin 59 p# biomarker 59 Zemplar Capsules 59 capecitabine Xeloda 59 Pegasys plus Copegus 59 Glatiramer Acetate 59 regorafenib 59 vismodegib 59 lupus nephritis 59 tenofovir emtricitabine 59 ruboxistaurin 59 CAELYX 59 STEP BD 59 phase 2a 59 dose escalation trial 59 blinded randomized 59 Kaplan Meier analysis 59 chemotherapeutic regimen 59 Neoadjuvant 59 evaluating Actimmune 59 REYATAZ R 59 SPIRIT FIRST 59 iclaprim 59 neoadjuvant treatment 59 tipranavir 59 recurrent herpes labialis 59 verteporfin 59 ganetespib 59 GSK# [001] 59 VIRAMUNE XR 59 prospective multicenter randomized 59 ROCKET AF 59 Viramidine 59 isavuconazole 59 landmark ATHENA 59 Denufosol 59 amrubicin 59 pharmacodynamic parameters 59 Stedivaze 59 HuMax CD# 59 antiangiogenic therapy 59 ONTAK 59 Vicriviroc 59 RE LY trial 59 #mg ATC 59 multicenter randomized clinical 59 ABC/3TC 59 dose escalation Phase 59 trastuzumab DM1 59 FOLFOX6 chemotherapy regimen 59 BARACLUDE ® 59 daily subcutaneous injections 59 evaluable subjects 59 HCl capsules 59 varespladib 59 CTAP# Capsules 59 Fluorouracil 59 Hepatotoxicity 59 Genasense 59 clevudine 59 adjuvant tamoxifen 59 Coronary Artery Bypass Graft 59 Levetiracetam 59 mitomycin 59 TAXUS ATLAS 59 Alvesco R 59 unstable angina pectoris 59 EDARBI 59 refractory AML 59 cyclophosphamide methotrexate 59 cidofovir 59 palivizumab 59 Egrifta 59 sevelamer 59 Arikace 59 BCX# 59 antiretroviral naïve 59 Phase III 59 Enzyme Replacement Therapy 59 subcutaneously administered 59 Navelbine 59 PREZISTA r 59 Capesaris 59 virus HCV protease inhibitor 59 Rituxan rituximab 59 ALGRX 59 antithymocyte globulin 59 rosuvastatin #mg 59 paclitaxel Taxol 59 AVERROES 59 ularitide 59 Ozarelix 59 Engerix B 59 adecatumumab 59 KRN# 59 multicenter Phase III 59 ACTEMRA TM 59 relapsed CLL 59 NCCTG N# 59 irbesartan 59 teduglutide 59 receptor inhibitor 59 QVA# 59 Candesartan 59 Darusentan 59 daclizumab 59 β blockers 59 receptor tyrosine kinase inhibitor 59 dextromethorphan quinidine 59 sorafenib Nexavar ® 59 HIV HCV coinfected 59 MVA MUC1 IL2 59 BEXXAR Therapeutic Regimen 59 #mg/m# [002] 59 EDEMA3 59 romiplostim 59 coadministration 59 immunomodulatory therapy 59 Anacetrapib 59 TEMODAL 59 olaparib 59 PRECiSE 59 tipifarnib 59 sargramostim 59 Ontak 59 amoxicillin clavulanate 59 GSK# [002] 59 mg BID dose 59 antiretroviral naive 59 placebo controlled clinical trials 59 MAXY G# 59 liposome injection 59 preclinical pharmacokinetic 59 DSMB recommended 59 GetGoal Phase III 59 FIRMAGON 59 heFH 59 ARCALYST ® rilonacept 59 ITAX 59 antioxidant supplementation 59 Cytoxan 59 5 fluorouracil leucovorin 59 HGS ETR1 59 HuLuc# 59 Phase IIa trials 59 gastrointestinal stromal tumors GIST 59 NAVISTAR R 59 basal bolus regimen 59 efavirenz EFV 59 Ovarian Cancer Screening 59 Zybrestat 59 beta 1a 59 FOLOTYN ® 59 tolerability pharmacokinetics 59 mg administered orally 59 refractory gout 59 FASLODEX 59 Valortim R 59 panitumumab Vectibix 59 dose escalation 59 Romiplostim 59 pegylated interferons 59 Tasigna nilotinib 59 ONTARGET 59 idiopathic thrombocytopenic purpura 59 Hyphanox 59 anti leukemic 59 octreotide LAR 59 SILENOR 59 Belatacept 59 OvaRex R 59 daunorubicin 59 metastatic renal cell carcinoma 59 PEGPH# 59 paclitaxel carboplatin 59 antiangiogenic agents 59 caspofungin 59 Clinical Outcomes Utilizing Revascularization 59 pemetrexed Alimta 59 ciclosporin 59 evaluating satraplatin 59 Phase IIb trials 59 prospective randomized multicenter 59 gp# vaccine 59 Phase #b/#a trial 59 MabCampath 59 virologic response 59 prospective multicenter 59 registrational 59 bevacizumab Avastin ® 59 severe neutropenia 59 letrozole Femara 59 IFN alpha XL 59 MEVACOR 59 HDL Selective Delipidation 59 QTc prolongation 59 malignant ascites 59 Platinol ® cisplatin 58 DLTs 58 PROMUS R 58 Hepatocellular Carcinoma HCC 58 mitoxantrone plus 58 trastuzumab Herceptin ® 58 evaluating REVLIMID 58 ORAL Sync 58 Altastaph 58 dexamethasone Decadron 58 clevidipine 58 Pertuzumab 58 PEARL SC 58 Gemzar ® 58 ZYBRESTAT fosbretabulin 58 Ophena 58 VADT 58 ON #.Na 58 Deforolimus 58 IIIa inhibitor 58 flutamide 58 lamotrigine 58 FOLFOX6 58 Myocet 58 recurrent VTE 58 ENGAGE AF TIMI 58 antiarrhythmic drug 58 Patency 58 aldosterone antagonists 58 candidate CRLX# 58 anagrelide 58 morphometric vertebral fractures 58 Phase Ib IIa clinical 58 uridine triacetate 58 SCH # 58 FROVA 58 Aptivus 58 endometrial carcinoma